REDHILL BIOPHAR/S (NASDAQ:RDHL) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research cut shares of REDHILL BIOPHAR/S (NASDAQ:RDHL) from a buy rating to a hold rating in a research note issued to investors on Saturday morning, Zacks.com reports.

According to Zacks, “RedHill Biopharma Ltd. is a specialty biopharmaceutical company, primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases. RedHill promotes the gastrointestinal drug Aemcolo(TM) in the U.S. and is planning to launch Talicia(TM) in the U.S. for the treatment of Helicobacter pylori (H. pylori) infection in adults. RedHill’s key clinical late-stage development programs include: RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; RHB-102 (Bekinda(TM)), for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; ABC294640 (Yeliva(TM)), a first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 2a study for cholangiocarcinoma; RHB-106, an encapsulated bowel preparation, and RHB-107. “

Several other brokerages also recently weighed in on RDHL. ValuEngine raised REDHILL BIOPHAR/S from a hold rating to a buy rating in a research note on Tuesday, January 28th. HC Wainwright reaffirmed a buy rating and set a $18.00 target price on shares of REDHILL BIOPHAR/S in a research note on Wednesday, November 20th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $15.94.

Shares of RDHL stock opened at $4.52 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.22 and a quick ratio of 2.08. The company has a market cap of $108.25 million, a price-to-earnings ratio of -3.30 and a beta of 1.50. The stock has a 50 day simple moving average of $5.49 and a 200-day simple moving average of $6.43. REDHILL BIOPHAR/S has a 1-year low of $4.50 and a 1-year high of $9.20.

Several hedge funds have recently made changes to their positions in RDHL. Boston Partners acquired a new position in shares of REDHILL BIOPHAR/S during the 3rd quarter worth approximately $190,000. Disciplined Growth Investors Inc. MN raised its stake in REDHILL BIOPHAR/S by 0.4% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 1,145,014 shares of the biotechnology company’s stock valued at $8,061,000 after purchasing an additional 4,550 shares during the last quarter. Ingalls & Snyder LLC acquired a new position in REDHILL BIOPHAR/S in the 4th quarter valued at $119,000. Creative Planning raised its stake in REDHILL BIOPHAR/S by 35.7% in the 4th quarter. Creative Planning now owns 385,814 shares of the biotechnology company’s stock valued at $2,342,000 after purchasing an additional 101,464 shares during the last quarter. Finally, ARK Investment Management LLC raised its stake in REDHILL BIOPHAR/S by 4.5% in the 4th quarter. ARK Investment Management LLC now owns 58,373 shares of the biotechnology company’s stock valued at $354,000 after purchasing an additional 2,487 shares during the last quarter. 29.57% of the stock is owned by institutional investors and hedge funds.

REDHILL BIOPHAR/S Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.

See Also: What is a Swap?

Get a free copy of the Zacks research report on REDHILL BIOPHAR/S (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.